During the past decade, Van Yuzuncu Yil University Hospital; Medical Oncology conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Van Yuzuncu Yil University Hospital; Medical Oncology" are "Advanced or Metastatic Esophageal Squamous Cell Carcinoma" (1 trials) and "Esophageal Squamous Cell Carcinoma" (1 trials). Many other conditions were trialed in "Van Yuzuncu Yil University Hospital; Medical Oncology" in a lesser frequency.

Most popular intervention types in "Van Yuzuncu Yil University Hospital; Medical Oncology" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (1 trials), "Atezolizumab Matching Placebo" (1 trials), "Lomvastomig" (1 trials), "Nivolumab" (1 trials) and "Tiragolumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Van Yuzuncu Yil University Hospital; Medical Oncology" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Van Yuzuncu Yil University Hospital; Medical Oncology". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Van Yuzuncu Yil University Hospital; Medical Oncology, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Van Yuzuncu Yil University Hospital; Medical Oncology, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".